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background: Glucose control after cardiac surgery is a national quality measure, but data on cost implications of glucose management is lacking. 
This study examines the costs associated with hyperglycemia in patients with and without pre-existing diabetes after cardiac surgery.
Methods: Prospectively collected clinical data from the Cardiothoracic Surgical Trials Network were merged with financial data from University 
Health Consortium. Clinical data include patient history, glucose management, glycemic events and infections (CDC/NHSN criteria), and 
cardiovascular, neurological, pulmonary and renal complications (ICD-9 codes). Costs associated with hyperglycemia (glucose >180mg/dL) were 
estimated using a generalized linear model.
results: In 4317 patients, mean age 64±12 years, 23% had diabetes. The most common procedures were isolated valve (31%), isolated CABG 
(29%), and CABG/valve (12%). 44% of patients experienced hyperglycemic events. Complications were more common in non-diabetics with 
hyperglycemia (26% vs. 20.6 %, p<0.001) and additional hospitalization cost associated with hyperglycemia was only seen in patients without prior 
diabetes (Table).
conclusions: Postoperative hyperglycemia is associated with greater resource utilization among patients without history of diabetes, but not 
those with preexisting diabetes. Along with well established patient safety concerns, considerable cost is at stake in our ability to optimize glucose 
management after cardiac surgery.
Cost, mean (95% CL)
Non-diabetes Diabetes
Unadjusted
Total
Adjusted**
Incremental
Unadjusted
Total
Adjusted Incremental
Hyperglycemic*
$38,642
(36403, 40881)
$2,629
(1439, 3866)
$36,959
(34219, 39699)
$-1741
(-4306, 935)
Non-
hyperglycemic
$28,987
(27797, 30177)
(Ref)
$40,661
(35659, 45663)
(Ref)
Notes: 
* Hyperglycemic: at least one glucose measurement is greater than 180 mg/dL in the first 48 hours after surgery;
**Generalized linear model adjusting for demographics, baseline labs (white blood cells, creatinine, hemoglobin), corticosteroids, comorbidities 
(congestive heart failure, ejection fraction, prior cardiac surgery, lung disease), surgery time, sternotomy, surgery type (elective, urgent, emergent) , 
procedure type, interaction term of hyperglycemic and diabetes.
